AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04270591
Drug: Glumetinib
RxNorm normalized name: Glumetinib
DrugBank: Glumetinib (DB15630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product will be orally administrated when fasting at dose level of 300mg QD
Trial: NCT03311477
Drug: ABBV-399
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion
Trial: NCT03186053
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: .Loading dose followed by continuous infusion in operation
Trial: NCT01886859
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01886859
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01901432
Drug: Givinostat
RxNorm normalized name: givinostat
DrugBank: Givinostat (DB12645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part A patients will treated in dose levels at the following daily doses of Givinostat:~* 50 mg b.i.d.,~* 100 mg b.i.d.;~* 150 mg b.i.d.,~* 200 mg b.i.d.;~* 150 mg t.i.d.;~* 200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.~In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
Trial: NCT00379288
Drug: mometasone furoate combination MDI 200/10 mcg BID
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
Trial: NCT00379288
Drug: Fluticasone/Salmeterol 250/50 mcg BID
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: F/SC 250/50 twice daily for 1 year
Trial: NCT00379288
Drug: Fluticasone/Salmeterol 500/50 mcg BID
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: F/SC 500/50 twice daily for 1 year
Trial: NCT00310934
Drug: methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00310934
Drug: buprenorphine / methadone sequence
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00336700
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500mg/m2 IV over 150 min IV q 2 weeks 4 months
Trial: NCT04561648
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before removing the introducer sheath, the 2nd operator will pass the missing UFH dose to the first operator to reach 100 IU per kg of body weight in a 10 ml syringe mixed with 0.9% saline solution. The blinded first operator will administer this without knowing if it is saline or the supplemental dose of unfractionated heparin.
Trial: NCT03332186
Drug: BMS-986231
RxNorm normalized name: BMS-986231
DrugBank: Cimlanod (DB14983)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion administration
Trial: NCT03028142
Drug: 1.5 mg RPL554 plus tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03028142
Drug: 6 mg RPL554 plus tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03028142
Drug: Placebo plus tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02194972
Drug: Pectin
RxNorm normalized name: Pectin
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
Trial: NCT04318704
Drug: Ifenprodil
RxNorm normalized name: ifenprodil
DrugBank: Ifenprodil (DB08954)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifenprodil 20 mg TID
Trial: NCT02981030
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women seeking medical abortion will be offered the option to take mifepristone at home
Trial: NCT02342587
Drug: Lapatinib
RxNorm normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
Trial: NCT04475848
Drug: RO6953958
RxNorm normalized name: RO6953958
DrugBank: RO6953958 (DB17081)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: RO6953958 will be administered in an adaptive manner. The starting dose is planned to be 5 milligrams (mg).~Part 2: The starting dose is planned to be 45 mg.~Part 3: RO6953958 will be administered QD following a standardized breakfast on Day 3 to Day 14 at the maximum dose QD that was tested in the ongoing Part 2 (MAD).
Trial: NCT00336700
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg/d Daily, oral 12 months
Trial: NCT04475848
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam will be administered as single intervenous (IV) bolus injection of 100 micrograms (ug) on Day 1 and Day 13, and as single oral dose of 300 ug on Day 2 and Day 14.
Trial: NCT02283372
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02283372
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02981030
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
Trial: NCT01618253
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
Trial: NCT02952534
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rucaparib will be administered daily
Trial: NCT00943839
Drug: sunitinib malate
RxNorm normalized name: Sunitinib Malate
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01437618
Drug: FOLFOXIRI plus bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by~* IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by~* OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with~* l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by~* 5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks
Trial: NCT00133562
Drug: Alanyl-glutamine
RxNorm normalized name: ALANYL-GLUTAMINE
DrugBank: Alanyl glutamine (DB11876)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02579863
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: oral capsules
Trial: NCT02579863
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral tablets
Trial: NCT02855086
Drug: Cetuximab-IRDye 800CW
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered intravenously (IV)
Trial: NCT01800682
Drug: Tramodol Extended-Release (ER)
RxNorm normalized name: tramadol Extended Release Oral Capsule
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
Trial: NCT00396760
Drug: aprotinin or tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01291823
Drug: gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gefitinib 250mg/day
Trial: NCT00000500
Drug: aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000500
Drug: carotene
RxNorm normalized name: Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00687687
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
Trial: NCT00687687
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
Trial: NCT02334982
Drug: TAK-137
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-137 tablets
Trial: NCT00480402
Drug: 200 mg of Progesterone
RxNorm normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of 200 mg of Progesterone
Trial: NCT00480402
Drug: 400 mg Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administration of 400 mg Progesterone
Trial: NCT01133795
Drug: Midodrine plus Albumin
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
Trial: NCT00663702
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subcutaneous injection, 125 mg/mL, once weekly, 48 months
Trial: NCT00626990
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
Trial: NCT04490590
Drug: Chidamide+ Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive the treatment of and chidamide and etoposide capsule, and those who have achieved CR（complete response）or PR（partial response）or SD(stable disease)will continue the treatment.
Trial: NCT02630108
Drug: Ultra-fluid lipiodol
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
Trial: NCT02154464
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02738203
Drug: Vaginal 2% Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
Trial: NCT02738203
Drug: Surgical Lubricant Jelly
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
Trial: NCT00064233
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00574873
Drug: Bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Trial: NCT00962312
Drug: lapatinib ditosylate
RxNorm normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT04085601
Drug: APL-2
RxNorm normalized name: APL-502
DrugBank: APL-502 (DB17473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complement (C3) Inhibitor
Trial: NCT02224625
Drug: Active Comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT03328234
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45-50mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Trial: NCT03328234
Drug: Platinum-Based Drug
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
Trial: NCT03328234
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 135-150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
Trial: NCT03328234
Drug: Platinum-Based Drug
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin or Lobaplatin or Cisplatin, 50-80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
Trial: NCT01716806
Drug: brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1.8 mg/kg every 3 weeks by IV infusion
Trial: NCT01716806
Drug: bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 70 mg/m\^2 by IV infusion on Days 1 and 2 of 3-week cycle
Trial: NCT01716806
Drug: dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 375 mg/m\^2 every 3 weeks by IV infusion
Trial: NCT01716806
Drug: nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 mg/kg every 3 weeks by IV infusion
Trial: NCT00574873
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
Trial: NCT02323451
Drug: Sodium Hyaluronate Injection
RxNorm normalized name: Sodium Hyaluronate Injection
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-articular injection
Trial: NCT03904823
Drug: famitinib po
RxNorm normalized name: Axitinib
DrugBank: Famitinib (DB11741)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
Trial: NCT03904823
Drug: HS-10296 po
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients would be treated with famitinib po combined with HS-10296 po till progression disease or withdrawal from the study.
Trial: NCT03719430
Drug: APX005M
RxNorm normalized name: CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APX005M is a CD40 agonistic monoclonal antibody 0.3 mg/kg IV day 1 (21 day cycles)
Trial: NCT00727311
Drug: Rebetol (ribavirin; SCH 18908)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
Trial: NCT02942277
Drug: Coartem
RxNorm normalized name: Coartem
DrugBank: Artemether (DB06697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. Coartem will be dosed with food and administered over 3 days for a total of 6 doses, as per package insert and standard adult dosing
Trial: NCT01270035
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: To increase the ADA dose from 40 mg eow to 80 mg eow
Trial: NCT00534027
Drug: AMG 655
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 655 is a monoclonal antibody directed against TR-2.
Trial: NCT01587885
Drug: Omeprazole 20 mg + Sodium Bicarbonate 1100 mg
RxNorm normalized name: omeprazole / sodium bicarbonate
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Capsules, orally
Trial: NCT01587885
Drug: Omeprazole 20 mg
RxNorm normalized name: omeprazole 20 MG
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets, orally
Trial: NCT02930057
Drug: Celestone
RxNorm normalized name: Celestone
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
Trial: NCT00229437
Drug: TAK-128
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
Trial: NCT00229437
Drug: TAK-128
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
Trial: NCT00229437
Drug: TAK-128
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
Trial: NCT02930057
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
Trial: NCT01480388
Drug: Placebo/JNJ-39758979 (300 mg/d)
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
Trial: NCT01480388
Drug: JNJ-39758979 (10 mg)
RxNorm normalized name: JNJ-39758979
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Trial: NCT01480388
Drug: JNJ-39758979 (30 mg)
RxNorm normalized name: JNJ-39758979
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Trial: NCT00858377
Drug: Arm 1- Dose Escalation
RxNorm normalized name: peanut allergenic extract
DrugBank: Peanut (DB10553)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Trial: NCT00858377
Drug: Arm 1- Dose Expansion
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
Trial: NCT01480388
Drug: JNJ-39758979 (100 mg)
RxNorm normalized name: JNJ-39758979
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral adminstration once daily up to 48 weeks
Trial: NCT01480388
Drug: JNJ-39758979 (300 mg)
RxNorm normalized name: JNJ-39758979
DrugBank: JNJ-39758979 (DB18899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form = tablet, route = oral adminstration once daily for 48 weeks
Trial: NCT00377442
Drug: GK Activator (2)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg po
Trial: NCT02432885
Drug: Enalapril
RxNorm normalized name: Enalapril
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: up to 20mg bid
Trial: NCT00162448
Drug: BMS-394136
RxNorm normalized name: BMS-394136
DrugBank: BMS-394136 (DB12067)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 100 mg, Single dose, 1 day.
Trial: NCT02479555
Drug: Dexamethasone sodium phosphate injection, USP, 4 mg/mL
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.~Investigational Drug will be administered via Bullfrog Micro-Infusion Device.
Trial: NCT00249873
Drug: clopidogrel (SR25990C)
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration (tablets)